Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease
- Registration Number
- NCT00796679
- Lead Sponsor
- The University of Hong Kong
- Brief Summary
The purpose of this study is to test the hypothesis that selective vitamin D receptor activation reduces left ventricular hypertrophy and ameliorates inflammation and atherosclerosis in stage 3 -5 chronic kidney disease.
- Detailed Description
Cardiovascular disease is the leading cause of mortality and morbidity in patients with chronic kidney disease. According to a previous study, only 15.6% of the patients beginning dialysis therapy had a normal echocardiogram, with left ventricular hypertrophy, left ventricular dilatation and systolic dysfunction occurring in 40.7%, 28% and 15.6% of patients, respectively. In addition, these patients are at an accelerated risk of developing atherosclerosis. The Kidney Disease Outcome Quality Initiative guideline recently raised concerns of a high prevalence of vitamin D deficiency in chronic kidney disease patients not yet requiring dialysis treatment. In addition, very recent data suggested that vitamin D deficiency is an important predictor of mortality in end-stage renal disease patients. Furthermore, hemodialysis patients treated with paricalcitol, a selective vitamin D receptor activator, showed a significantly lower risk of cardiovascular death than those not receiving vitamin D therapy. A number of studies also showed positive benefit of vitamin D receptor activator treatment on regression of left ventricular hypertrophy in dialysis patients. However, there is so far no data in patients with stage 3 and 4 chronic kidney disease where a high prevalence of vitamin D deficiency and cardiac hypertrophy has been reported.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
-
Patient with stage 3 -5 chronic kidney disease (that is, eGFR < 60 ml/min per 1.73m2) diagnosed for more than 2 months and not expected to start dialysis within the next 12 months, and
-
Patient with screening echocardiography showing evidence of left ventricular hypertrophy
-
Patient has not received vitamin D therapy in the previous 4 weeks
-
For entry into the Treatment Phase, the subject must have:
- screening iPTH >= 55 pg/ml or 5.8pmol/L (determined by the Nichols second-generation assay or similar assay)
- serum calcium < 10.2 mg/dL (2.55 mmol/L)
- serum phosphorus =< 5.2mg/dL (1.68mmol/L)
- Ca*P product < 54 mg2/dL2 (4.36mmol2/L2)
- If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is of childbearing potential and practicing birth control measures.
-
Patients who provide informed consent for the study
- Patient with a history of an allergic reaction or significant sensitivity to vitamin D or vitamin D related compounds.
- Patient with history of renal stones
- Patient with current malignancy
- Patients with clinically significant gastrointestinal disease or liver disease
- Patient with acute renal failure in the recent three months
- Patient with a history of drug or alcohol abuse within six months prior to the screening phase
- Patient is known to be human immunodeficiency virus (HIV) positive.
- Patient with evidence of poor compliance with diet and medication.
- Patient currently receiving medications that may affect calcium, phosphorus metabolism such as calcitonin, cinacalcet, bisphophonates or vitamin D compounds (other than study drug), or other drugs that may affect calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy.
- Patients with active granulomatous disease
- Patient with pregnancy
- Patients currently receiving glucocorticoid steroid or other immunosuppressive treatment or had been administered glucocorticoid or other immunosuppressive treatment for more than 14 days within recent 6 months.
- Patients with contraindication for MRI examination
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 paricalcitol placebo 1 paricalcitol paricalcitol
- Primary Outcome Measures
Name Time Method Change in left ventricular mass index determined by MRI 1 year
- Secondary Outcome Measures
Name Time Method Change in left atrial and ventricular volumes, systolic and diastolic function, carotid intima-media thickness, flow mediated dilation, pulse wave velocity, serum inflammatory and cardiac biomarkers, intact PTH, 24-hour urine protein and renal function 1 year
Trial Locations
- Locations (2)
University of Hong Kong, Queen Mary Hospital
ðŸ‡ðŸ‡°Hong Kong, Hong Kong
Queen Mary Hospital
ðŸ‡ðŸ‡°Hong Kong, Hong Kong